Mechanistic evaluation of butea monosperma using in vitro and in vivo murine models of bronchial asthma

International Journal of Research in Ayurveda and Pharmacy

Volumn 4, Issue 3, 2013, Pages 322-331

  Shirole, R L ^a   Kshatriya, A A ^a   Sutariya, B K ^a   Saraf, M N ^a  

^a BOMBAY COLLEGE OF PHARMACY   (India)

Author keywords

Anti inflammatory; Butea monosperma; Lipopolysaccharide; Lipoxygenase

Indexed keywords

ALBUMIN; ANTIASTHMATIC AGENT; BUTEA MONOSPERMA EXTRACT; KETOTIFEN; LIPOXYGENASE; NITRATE; NITRITE; PLANT EXTRACT; PROTEIN; ROFLUMILAST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; BUTEA MONOSPERMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME ASSAY; FEMALE; FRACTIONATION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LD 50; LEUKOCYTE DIFFERENTIAL COUNT; LUNG HOMOGENATE; LUNG LAVAGE; MAST CELL DEGRANULATION; NONHUMAN; OUTCOME ASSESSMENT; RAT;

EID: 84897918200     PISSN: 22774343     EISSN: 22293566     Source Type: Journal    
DOI: 10.7897/2277-4343.04304     Document Type: Article

References (51)

1. Wong FS, Koh SK. Advances in Immunopharmacology of Asthma. Biochem Pharmacol. 2000; 59: 1323-35 http://dx.doi.org/10.1016/S0006-2952(99)00378-0
2. Barnes PJ, KF Chung, and CP Page, Inflammatory mediators of asthma: an update. Pharmacological reviews. 1998; 50(4): 515-596 PMid:9860804
3. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. CHEST Journal 2004; 125(4): 1378-1386 http://dx.doi.org/10.1378/chest.125.4.1378
4. Fernandes LB, Goldie RG. The single mediator approach to asthma therapy, is it so unreasonable?.Curr Opin Pharmacol 2003; 3: 251-6 http://dx.doi.org/10.1016/S1471-4892(03)00042-0
5. Adamko D, Odemuyiwa SD, Moqbel R, Redwan M. The eosinophil as a therapeutic target in asthma: beginning of the end, or end of the beginning. Curr Opin Pharmacol 2003; 3: 227-32 http://dx.doi.org/10.1016/S1471-4892(03)00040-7
6. Kirtikar K, Basu BD. Indian medicinal plants. 1975.
7. Jain SK, Medicinal plants. National Book Trust, India: distributors, Thomson Press (India). 1979
8. Wagner H, Geyer B. Isobutrin and butrin, the antihepatotoxic principles of Butea monosperma flowers. Planta Med. 1986; 52: 77. http://dx.doi.org/10.1055/s-2007-969083
9. Mengi SA, Deshpande SG. Anti-inflammatory activity of Butea monosperma flowers. Fitoterapia. 1999; 70: 521. http://dx.doi.org/10.1016/S0367-326X(99)00076-3
10. Somani R, Kasture S, Singhai AK. Antidiabetic potential of Butea monosperma in rats. Fitoterapia. 2006; 77(2): 86-90 http://dx.doi.org/10.1016/j.fitote.2005.11.003 PMid:16376023
11. Shah KG, Baxi AJ. Phytochemical studies and antiestrogenic activity of Butea frondosa (Butea monosperma) flowers. Ind J Pharmacol Sci. 1990; 52: 272
12. Gupta S, Ravindranath B, Seshadri T. The glucosides of Butea monosperma. Phytochemistry. 1970; 9(10): 2231-2235 http://dx.doi.org/10.1016/S0031-9422(00)85390-X
13. Shahavi V and Desai S. Anti-inflammatory activity of Butea monosperma flowers. Fitoterapia. 2008;79(2):82-85 http://dx.doi.rg/10.1016/j.fitote.2007.06.014 PMid:17904309
14. Aye AT, Aye MH, Hnin P and Maung H. Isolation and Characterization of Flavonoids from the Flowers of Butea monosperma. The Jour. Myan. Acad. Arts & Sc. 2004; 2(1): 86-89
15. Shinde U et al., Mast cell stabilizing and lipoxygenase inhibitory activity of Cedrus deodara (Roxb.) Loud. wood oil. Indian journal of experimental biology. 1999; 37(3): 258. PMid:10641156
16. OECD 423. OECD guidelines for testing of chemicals. OECD Publishing, 1998.
17. Bradley PP, Christensen RD and Rothstein G, Cellular and extracellular myeloperoxidase in pyogenic inflammation. Blood. 1982; 60(3): 618 PMid:6286012
18. Leza JC, et al. The effects of stress on homeostasis in JCR-LA-cp rats: the role of nitric oxide. Journal of Pharmacology and Experimental Therapeutics. 1998; 286(3):1397. PMid:9732403
19. Lowry O et al. Protein estimation with the Folin phenol reagent. J Biol Chem. 1951; 193:265-275. PMid:14907713
20. Doumas B. and Biggs H. Estimation of albumin in serum. Standard Methods. Clin. Chem. 1972; 7:175-188.
21. Uvnas B. Mast cells and Histamine release. Ind J Pharmac. 1969; 1: 23-2.
22. Okayama Y, Ra C, Saito H. Role of mast cells in airway remodeling. Current opinion in immunology 2007; 19(6): 687-693. http://dx.doi.org/10.1016/j.coi.2007.07.018 PMid:17761410
23. Stanworth DR. Immediate Hypersensitivity. In: Neuberger A, Tatum EL. (Eds.) The Molecular Basis of the Allergic Response. Amsterdam: North Holland Publishing Company; 1973. p.73.
24. Galli S and lantz CS Allergy. In fundamental Immunology. (Paul W, ed.) Raven Press. 1998 p.1127-1174.
25. Geetha VS, Vishwanathan S, Kameswaran L. Comparison of total alkaloids of Tylospora indica and Disodium cromoglycate on mast cell stabilization. Ind J Pharmacol. 1981; 13: 199-201
26. Cheong H, Ryu SY, Oak MH, Cheon SH, Yoo GS, Kim KM. Studies of structure activity relationship of flavonoids for the antiallergic actions. Archives of pharmacal research. 1998; 21(4): 478-480. http://dx.doi.org/10.1007/BF02974647 PMid:9875480
27. Havsteen B. Flavonoids, a class of natural products of high pharmacological potency. Biochemical pharmacology. 1983; 32(7): 1141 http://dx.doi.org/10.1016/0006-2952(83)90262-9
28. Pathak D, Pathak K, Singla A. Flavonoids as medicinal agentsrecent advances. Fitoterapia. 1991; 62: 371-389.
29. Israel E et. al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. JAMA: the journal of the American Medical Association. 1996;275(12):931-936. http://dx.doi.org/10.1001/jama.1996.03530360041036
30. Lau GTY, Huang H, and Leung LK. Butein downregulates phorbol 12-myristate 13-acetate-induced COX-2 transcriptional activity in cancerous and non-cancerous breast cells. European journal of pharmacology 2010; 648(1-3):24-30. http://dx.doi.org/10.1016/j.ejphar.2010.08.015 PMid:20826149
31. Hatzelmann Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H. The preclinical pharmacology of roflumilast A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease Pulmonary Pharmacology & Therapeutics.2010;23:235-256.http://dx.doi.org/10.1016/j.pupt. 2010.03.011 PMid:20381629
32. Bochner BS. Adhesion molecules as therapeutic targets. Immunology and allergy clinics of North America. 2004; 24(4): 615-630.http://dx.doi.org/10.1016/j.iac.2004.06.003 PMid:15474862
33. Yang RB et al. Toll-like receptor-2 mediates lipopolysaccharideinduced cellular signalling. Nature. 1998; 395(6699):284-288. http://dx.doi.org/10.1038/26239 PMid:9751057
34. Ohkawara Y. et al. Human lung mast cells and pulmonary macrophages produce tumor necrosis factor-alpha in sensitized lung tissue after IgE receptor triggering. American journal of respiratory cell and molecular biology. 1992; 7(4):385. http://dx.doi.org/10.1165/ajrcmb/7.4.385 PMid:1382477
35. Finotto S et al. TNF-alpha production by eosinophils in upper airways inflammation nasal polyposis). The Journal of Immunology. 1994; 153(5): 2278. PMid:8051424
36. Abdelaziz M et al. The effect of conditioned medium from cultured human bronchial epithelial cells on eosinophil and neutrophil chemotaxis and adherence in vitro. American journal of respiratory cell and molecular biology, 1995; 13(6):728. http://dx.doi.org/10.1165/ajrcmb.13.6.7576711 PMid:7576711
37. Bodey K et al. Cytokine profiles of BAL T cells and T cell clones obtained from human asthmatic airways after local allergen challenge. Allergy. 1999; 54(10):1083-1093. http://dx.doi.org/10.1034/j.1398-9995.1999.00889.x PMid:10536887
38. Kips J, Tavernier J, and Pauwels R. Tumor necrosis factor causes bronchial hyperresponsiveness in rats. The American review of respiratory disease. 1992; 145(2 Pt 1):332. http://dx.doi.org/10.1164/ajrccm/145.2_Pt_1.332 PMid:1736737
39. Lefort J et al. Systemic administration of endotoxin induces bronchopulmonary hyperreactivity dissociated from TNF-a formation and neutrophil sequestration into the murine lungs. The Journal of Immunology. 1998; 161(1):474. PMid:9647258
40. Corteling R, Wyss D and Trifilieff A, In vivo models of lung neutrophil activation. Comparison of mice and hamsters. BMC pharmacology, 2002; 2(1): 1. http://dx.doi.org/10.1186/1471-2210-2-1 PMid:11806755 PMCid:64786
41. Asti C et al. Lipopolysaccharide-induced Lung Injury in Mice. I. Concomitant Evaluation of Inflammatory Cells and Haemorrhagic Lung Damage. Pulmonary Pharmacology & Therapeutics. 2000; 13(2):61-69.http://dx.doi.org/10.1006/pupt.2000.0231 PMid:10799283
42. Barnes PJ and Belvisi M. Nitric oxide and lung disease. Thorax. 1993; 48(10): 1034-1043. http://dx.doi.org/10.1136/thx.48.10.1034 PMid:7903007 PMCid:464825
43. Taylor, Robinson AW et al. The role of TH1 and TH2 cells in a rodent malaria infection. Science. 1993; 260(5116):1931-1934.
44. Xie Q, Kashiwabara Y and Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. Journal of Biological Chemistry. 1994; 269(7): 4705-4708. PMid:7508926
45. Colasanti M. et, al. Human ramified microglial cells produce nitric oxide upon Escherichia coli lipopolysaccharide and tumor necrosis factor a stimulation. Neuroscience letters. 1995; 200(2):144-146. http://dx.doi.org/10.1016/0304-3940(95)12101-9
46. Kwak HJ et. al. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-B, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. Journal of Pharmacology and Experimental Therapeutics. 2005; 315(3): 1188-1195. http://dx.doi.org/10.1124/jpet.105.092056 PMid:16126838
47. Rasheed Z et. al. Butrin, Isobutrin, and Butein from Medicinal Plant Butea monosperma Selectively Inhibit Nuclear Factor-B in Activated Human Mast Cells: Suppression of Tumor Necrosis Factor-a, Interleukin (IL)-6, and IL-8. Journal of Pharmacology and Experimental Therapeutics. 2010;333(2):354. http://dx.doi.org/10.1124/jpet.109.165209PMid:20164300 PMCid:2872957
48. Van De Graaf EA et al., Respiratory membrane permeability and bronchial hyperreactivity in patients with stable asthma: effects of therapy with inhaled steroids. American Journal of Respiratory and Critical Care Medicine. 1991; 143(2):362-368. http://dx.doi.org/10.1164/ajrccm/143.2.362 PMid:1990954
49. Persson CG. Role of plasma exudation in asthmatic airways. The Lancet. 1986; 328(8516):1126-1129. http://dx.doi.org/10.1016/S0140-6736(86)90533-7
50. Saria A et. al. Vascular protein leakage in various tissues induced by substance P, capsaicin, bradykinin, serotonin, histamine and by antigen challenge. Naunyn-Schmiedeberg's archives of pharmacology.1983;324(3):212-218.http://dx.doi.org/10.1007/BF 0503897
51. Holgate S. Mediator and cellular mechanisms in asthma. The Philip Ellman lecture 1990. Journal of the Royal College of Physicians of London. 1990; 24(4): 304. PMid:2258848